Lung microbiota of patients on ECMO for ARDS due to COVID-19

The purpose of the study was to elucidate the impact of ECMO treatment on the lung microbiota in patients with ARDS. We evaluated the lung microbiota (bacterial, fungal, and viral flora) with and without ECMO by comparing 5 patients on ECMO with 8 patients not on ECMO. Bronchoalveolar lavage fluid samples were collected from ARDS patients with COVID-19 within 24 hours of ARDS diagnosis to perform 16S rRNA, fungal ITS1 profiling and shotgun sequencing

本研究旨在阐明体外膜肺氧合（Extracorporeal Membrane Oxygenation, ECMO）治疗对急性呼吸窘迫综合征（Acute Respiratory Distress Syndrome, ARDS）患者肺部微生物群的影响。本研究通过对比5名接受ECMO治疗的患者与8名未接受该治疗的患者，评估了有无ECMO治疗时的肺部微生物群（细菌、真菌与病毒菌群）。研究人员于ARDS确诊后24小时内，从新型冠状病毒肺炎（COVID-19）合并ARDS的患者体内采集支气管肺泡灌洗液（Bronchoalveolar Lavage Fluid, BALF）样本，用于开展16S核糖体RNA（16S rRNA）、真菌ITS1分型及鸟枪法测序。